Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Reducing the Burden of Morphine-Induced Harm in Pediatric Oncology Patients by Identifying and Validating Genetic Variants Involved in Morphine Processing

EF 2024-25

Résumé
The treatment of cancer in children is often accompanied by the child experiencing high amounts of pain, which is reported to be one of the most frightening and distressing symptoms. Examples of these painful side effects include mucositis, pancreatitis, avascular necrosis and neuropathy, which require opioids (e.g. morphine) to be manageable. Morphine is a generally safe option to manage pain in children with cancer; however, some children will experience severe adverse reactions, including respiratory depression, impaired cognition, and sometimes even death. The likelihood of experiencing these morphine-induced adverse reactions can be explained by genetic variation in genes involved in morphine transport, metabolism, and signalling pathways. This research aims to provide a better understanding of how variation in genes involved in these processes leads to morphine-induced adverse reactions, and how this can guide the implementation of safer pain management treatment strategies. I propose to achieve this by first investigating the burden of morphine-induced adverse reactions in pediatric cancer patients, and then determining causative genetic variations that result in these adverse reactions. Lastly, I will conduct opioid sensitivity assays to validate these genetic variations as causing adverse reactions in children, in a pain management model developed using the simple nematode, Caenorhabditis elegans. Ultimately, the results of this study will help determine which patients will be most susceptible to developing morphine-induced adverse reactions. This will then inform clinical practice guidelines that provide recommendations for clinicians and families in the best course of treatment for pain management in pediatric cancer patients.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530148
Name
Simonson Laura P
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Reducing the Burden of Morphine-Induced Harm in Pediatric Oncology Patients by Identifying and Validating Genetic Variants Involved in Morphine Processing
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Drug-Related Toxicities; Morphine; Opioids; Pain; Pain Management; Pharmacogenomics; Precision Medicine
Abstract
The treatment of cancer in children is often accompanied by the child experiencing high amounts of pain, which is reported to be one of the most frightening and distressing symptoms. Examples of these painful side effects include mucositis, pancreatitis, avascular necrosis and neuropathy, which require opioids (e.g. morphine) to be manageable. Morphine is a generally safe option to manage pain in children with cancer; however, some children will experience severe adverse reactions, including respiratory depression, impaired cognition, and sometimes even death. The likelihood of experiencing these morphine-induced adverse reactions can be explained by genetic variation in genes involved in morphine transport, metabolism, and signalling pathways. This research aims to provide a better understanding of how variation in genes involved in these processes leads to morphine-induced adverse reactions, and how this can guide the implementation of safer pain management treatment strategies. I propose to achieve this by first investigating the burden of morphine-induced adverse reactions in pediatric cancer patients, and then determining causative genetic variations that result in these adverse reactions. Lastly, I will conduct opioid sensitivity assays to validate these genetic variations as causing adverse reactions in children, in a pain management model developed using the simple nematode, Caenorhabditis elegans. Ultimately, the results of this study will help determine which patients will be most susceptible to developing morphine-induced adverse reactions. This will then inform clinical practice guidelines that provide recommendations for clinicians and families in the best course of treatment for pain management in pediatric cancer patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Simonson, Laura P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~